Showing 4901-4910 of 10214 results for "".
- Cynosure Taps New CEOhttps://practicaldermatology.com/news/cynosure-taps-new-ceo/2461676/Nadav Tomer is Cynosure’s new chief executive officer, effective May 1, 2023. He succeeds Todd Tillemans, who will step down and will work closely with Mr. Tomer to ensure a smooth transition. "Nadav has an incredibly strong track record of operation
- EULAR News: Acelyrin's IL-17A Blocker Performs Well in PsAhttps://practicaldermatology.com/news/eular-news-acelyrins-il-17a-blocker-performs-well-in-psa/2461657/ACELYRIN, INC.’s IL-17A blocker izokibep demonstrated higher levels of response across psoriatic arthritis disease manifestations, according to 46-week data from a global Phase 2 trial of izokibep in psoriatic arthritis (PsA). Izokibep is a small pr
- ASA Honors Dr. Mark G. Lebwohl, Leo Pharmahttps://practicaldermatology.com/news/asa-honors-dr-mark-g-lebwohl-leo-pharma/2461652/Mark G. Lebwohl, MD and LEO Pharma received honors at the American Skin Association’s (ASA) annual Spring Gala, "We were proud to honor Dr. Mark Lebwohl and LEO Pharma for their dedication to the field of dermatology. Both honorees share in ASA
- Dr. James G. Krueger Joins ASA’s Board of Directorshttps://practicaldermatology.com/news/dr-james-g-krueger-joins-asas-board-of-directors/2461651/James G. Krueger, MD, PhD, will join the American Skin Association’s (ASA) Board of Directors. Dr. Krueger is the David Martin Carter Professor in Clinical Investigation and Head of the Laboratory for Investigative Dermatology at The Rockefeller University in&
- Aquavit Files Additional IND for New Toxin for Palmar Hyperhidrosishttps://practicaldermatology.com/news/aquavit-files-additional-ind-for-new-toxin-for-palmar-hyperhidrosis/2461625/Aquavit Holdings is asking the US Food and Drug Administration for an additional IND for DTX-024, a treatment of palmar hyperhidrosis using the company’s patented microchannel technology. DTX-024 is a highly purified and clinically tested injectable neuromodulator derived fr
- Molluscum Contagiosum Update: Two New Treatments Come Down the Pikehttps://practicaldermatology.com/news/molluscum-contagiosum-update-two-new-treatments-come-down-the-pike/2461621/Thanks to a busy pipeline, treating molluscum contagiosum may get easier. The U.S. Food and Drug Administration (FDA) accepted Novan’s New Drug Application (NDA) for Berdazimer Gel, 10.3% for the treatment of molluscum contagiosum with a Prescription Drug User Fee A
- Galderma's IL-31 Blocker Nemolizumab Wows in PNhttps://practicaldermatology.com/news/galdermas-il-31-blocker-nemolizumab-wows-in-pn/2461619/Galderma’s nemolizumab performed well in Prurigo Nodularis (PN). Nemolizumab is a first-in-class investigational monoclonal antibody directed against the IL-31 receptor alpha that blocks signaling from IL-31.Nemolizumab is an investigational drug and Galderma has not received
- Game On: Level Ex, GladskinMD Introduce Battle of the Biomehttps://practicaldermatology.com/news/game-on-level-ex-gladskinmd-introduce-battle-of-the-biome/2461618/Level Ex is teaming up with Gladskin to create custom, interactive gaming experiences that educate and train medical professionals on the science of endolysin technology and Gladskin’s new product line. As its first collaboration, the companies created a game called Batt
- Dermatologist Terrence A. Cronin Jr., MD, Named New AAD Presidenthttps://practicaldermatology.com/news/dermatologist-terrence-a-cronin-jr-md-named-new-aad-president/2461615/Terrence A. Cronin Jr., MD, FAAD, is the new President of the American Academy of Dermatology. He will start his one-year term at the close of the Academy's Annual Meeting. Dr. Cronin will also hold the same position for the American Academy of Dermatology Association, a sister
- Phase 3 Data: Dermavant's VTAMA Cream Performs Well in Adults and Kids with ADhttps://practicaldermatology.com/news/dermavant-vtama-cream-in-adults-and-kids-with-ad/2461612/Dermavant’s VTAMA (tapinarof) performed well in kids as young as 2 and adults with atopic dermatitis, according to topline results from the ADORING 2 Atopic Dermatitis Phase 3 Trial. VTAMA cream is a novel, aryl hydrocarbon receptor agonist, in development as a once-dai